CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed
Drug / intervention
EP HIV-1090biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00054860
NCT00054860Phase 1Completed
CompareCT.gov

A Phase I Dose-Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of the EP HIV-1090 DNA Vaccine in Healthy, HIV-1-Uninfected Adult Participants

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Feb 13, 2003·Updated Oct 14, 2021

In Brief

A Phase 1 clinical trial evaluating EP HIV-1090 for HIV Infections. Completed, across 5 sites in 2 countries.

Detailed Summary

The purpose of this study is to test the safety of an HIV DNA vaccine (EP HIV-1090) and to test whether or not the vaccine can stimulate immune system responses in HIV uninfected people. This vaccine uses only parts of the virus's DNA and cannot cause HIV infection.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesBotswana, United States
Collaborators--

Timeline

Phase 1CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 13, 2003
Study CompletionSep 1, 2005
TodayJul 2, 2026
Posted 23.4 years ago

Interventions

EP HIV-1090biological